Nasopharyngeal Squamous Cell Carcinoma
Associated Genetic Biomarkers
There are 11 clinical trials for nasopharyngeal squamous cell carcinoma, of which 8 are open and 3 are completed or closed. Of the trials that contain nasopharyngeal squamous cell carcinoma as an inclusion criterion, 1 is early phase 1 (0 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).
HPV, CDKN2A, and EBV are the most frequent gene inclusion criteria for nasopharyngeal squamous cell carcinoma clinical trials .
Carboplatin, cetuximab, and cisplatin are the most common interventions in nasopharyngeal squamous cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.